Catherine Polizzi

Patent Strategy + Prosecution; IP Due Diligence; Venture Intellectual Property; Emerging Companies + Venture Capital; Patent Trial and Appeal Board Litigation; Patent Litigation

Catherine is relied on by global brands and startups in the life sciences for her vigorous, ultra-effective approach to IP strategy and challenges, risk assessment, and due diligence work. Catherine helps emerging and established companies through the process of obtaining patents, and provides effective portfolio counseling and management, as well as strategic advice surrounding freedom of operation and other forms of IP assessment.

Catherine’s IP portfolio development and management acuity have been seminal to the valuation of deals, as well as the product pipeline successes of her clients, both evidence of the high-value work with which these leading companies entrust her.

She develops valuable, strategic portfolios around breakthrough therapies in a variety of areas, including: cancer, cancer immunotherapy, autoimmune diseases, inflammatory diseases, infectious diseases, cardiovascular diseases, metabolic disorders, neurodegenerative diseases.

Catherine is an acquisition and value enhancement driver, a critical conduit for companies as they grow from startup through IPO, exit, and beyond.